PERRIGO NET SALES GROW 15% IN THIRD QUARTER TO $163.6 MIL.
This article was originally published in The Tan Sheet
Executive Summary
PERRIGO NET SALES GROW 15% IN THIRD QUARTER TO $163.6 MIL., the company announced May 10. The private-label manufacturer reported increased sales for the three-month period ended March 31 in all three of the company's product categories -- OTC pharmaceuticals, personal care and vitamins -- with the largest increases in analgesic, cough and cold, and vitamin products.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: